Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Study to Evaluate Universal Allogeneic CAR-T Cells (QT-019B) Targeting CD19 and BCMA for the Treatment of Refractory Systemic Lupus Erythematosus

NCT07444307 is registered in ClinicalTrials.gov with Hangzhou Qihan Biotech Co., Ltd. as lead sponsor.

NCT NCT07444307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Study to Evaluate Universal Allogeneic CAR-T Cells (QT-019B) Targeting CD19 and BCMA for the Treatment of Refractory Systemic Lupus Erythematosus
Lead sponsor
Hangzhou Qihan Biotech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 15, 2025
Completion date
December 31, 2028
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)